Episode 321 ASCO24: CHAARTED-2 in prostate cancer - is the sequel as good as the original?

Update: 2024-06-01

Description

Christos Kyriakopoulos describes the outcome of this study, where cabazitaxel with abiraterone as combined with abiraterone alone in docetaxel refractory CRPC.

Comments

In Channel

Episode 336: Which patients are not suitable for 1st line EVP in bladder cancer

2024-07-2435:35

Episode 335: Novel immune therapies for renal cancer

2024-07-1937:31

Episodio 334 en español: Tres Uramigas ASCO 2024

2024-07-1136:33

Episode 333: The Uromigos Cup - The Netherlands

2024-07-0526:20

Episode 332: The Uromigos Cup - Germany's Entry

2024-06-2635:55

Episode 331: AUA 2024 NMIBC Highlights

2024-06-2133:56

Episode 330: ASCO 2024 Highlights

2024-06-1052:47

Episode 329: Japan in the Uromigos Cup qualifying round

2024-06-0730:48

Episode 328 ASCO24: Emergency podcast - what the NADINA trial means for preoperative GU cancer studies

2024-06-0526:32

Episode 327 ASCO24: CM901 and EV302 Efficacy and QOL Updates

2024-06-0424:02

Episode 326 ASCO24: KIM-1 in Renal Cancer

2024-06-0318:08

Episode 325 ASCO24: KN426 and the CLEAR trial - tissue based biomarkers for kidney cancer

2024-06-0333:44

Episode 324 ASCO24: SURE1 neoadjuvant sacituzumab govitecan in UC

2024-06-0220:43

Episode 323 ASCO24: TDXD in Bladder Cancer

2024-06-0229:47

Episode 322 ASCO24: The role of ctDNA in the TheraP trial (LuPSMA vs cabazitaxel in CRPC)